AlphAIAlphAI — Financial news for AI agents
investing.comOCT 52 min read$VSTM

Verastem shares get Buy rating reiterated by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

Original reporting
investing.com
Published Oct 5, 2026, 11:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VSTM
Bullish
high confidence
Mentioned
$VSTM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VSTMBullishMed
01

Why it matters

The reiteration of a Buy rating with a higher $18 target reflects confidence in the trial outcomes, likely prompting buying interest.

02

Market read

New clinical data and analyst upgrade provide fresh catalyst for VSTM, offering a short‑term trade idea.

03

What to watch

Potential regulatory hurdles and competition from other KRAS inhibitors.

Relevance 8/10Novelty 8/10Timing: today

Background

Analyst coverage update following presentation of new molecular analyses at the International Gynecologic Cancer Society meeting.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating with an $18 price target after new trial data showed 18% response in KRAS wild-type ovarian cancer and strong progression‑free survival results.

Expected impact

likely upward pressure as investors price in the strong efficacy signals and higher target price

Evidence & confidence

Analyst upgrade and concrete efficacy numbers are fresh, material information for a biotech stock.

Market effects

Sector

May boost sentiment for ovarian‑cancer and KRAS‑targeted therapy peers.

Regional

Limited to US biotech sector.

Global

Modest; primarily affects investors focused on oncology biotech.

Counterpoint

What could challenge this read

If later-stage data fails to confirm early signals, the stock could face a sharp correction.

Key entities

  • Company
    Verastem Oncology

    Biotech firm developing KRAS‑targeted therapies.

  • Analyst
    H.C. Wainwright

    Equity research firm providing the rating upgrade.

Read at source← All news

Related articles

OCT 2
$VSTMHighAI 9/10

Verastem presents new data on ovarian cancer drug combination

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

investing.com2 min
AUG 20
$VSTMHighAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

aol.com3 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min
AUG 6
$VSTMMed

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating

SEC EDGAR 8-K6 min